Thymopentin's best trial result was fewer myasthenia gravis relapses

What is thymopentin (TP-5)?

Thymopentin, sometimes labeled TP-5, is a synthetic five-amino-acid peptide (Arg-Lys-Asp-Val-Tyr) that matches residues 32-36 of thymopoietin, a calf-thymus protein. Thymopentin is not a whole protein. It is the minimal five-residue stretch of thymopoietin that early bioassays found sufficient to reproduce the parent molecule's reported activity in T-cell differentiation systems.

That "minimal active fragment" story is the correct discovery framing, and it is the one part of the popular narrative that holds up structurally. The claims built on top of it do not.

Is thymopentin the same family as thymosin alpha-1?

Thymopentin and thymosin alpha-1 come from separate discovery programs, not one "thymic hormone" family tree. Vendor pages routinely present thymopentin, thymosin alpha-1, thymosin beta-4, and thymalin as branches of a single family. Thymopoietin (thymopentin's parent) and thymosin fraction 5 (thymosin alpha-1's parent) were purified by different groups using different assays.

Treating them as one lineage moves evidence between molecules. A meta-analysis of synthetic thymic peptides used alongside chemotherapy in non-small cell lung cancer, covering 27 randomized trials and roughly 1,925 patients, found improved objective response and one-year survival ^[1]. The peptide most consistently identified as driving that signal was thymosin alpha-1, not thymopentin ^[1]. Lumping the two together misattributes evidence from one molecule's trial record to the other's origin story.

Separate reviews cover thymosin alpha-1 by indication, thymosin beta-4 in human trials, and the thymalin trial record.

Is thymopentin's parent, thymopoietin, a real thymic hormone?

Thymopoietin's gene encodes a nuclear envelope structural protein, now cataloged as TMPO (lamina-associated polypeptide 2), not a confirmed circulating immune hormone. When the gene was cloned, the protein turned out to have a role in nuclear architecture rather than a confirmed function as a secreted immune hormone.

The reclassification comes from the molecular biology literature, not from the clinical trial reports, and nearly all consumer coverage leaves it out. It directly undercuts the "five amino acids snipped from a proven hormone" pitch.

A peptide can still show biological activity in an assay regardless of what its full-length parent protein turns out to be. The point is narrower: the parent's identity is not the settled, secreted-hormone story the marketing implies.

Does thymopentin slow HIV progression?

Thymopentin slowed HIV progression only in one subgroup of a 48-week trial in 352 zidovudine-treated, asymptomatic subjects: those with longer prior zidovudine treatment ^[7].

The double-blind, placebo-controlled trial randomized subjects to thymopentin, 50 mg subcutaneously three times weekly, or placebo. In the stratum with longer prior treatment, thymopentin recipients had significantly fewer progression events than placebo. In the shorter-duration stratum, thymopentin showed no significant benefit and numerically more events in the treated group, and the treatment-by-stratum interaction was statistically significant ^[7].

A later re-analysis of the same trial cohort used viral load, CD4 count, and a resistance mutation to identify who was at higher risk of progression. It did not establish that thymopentin reliably altered that risk across the board ^[6]. The HIV result is inconsistent, not the broad immune restoration the "thymic peptide" category is sold on.

Does thymopentin help atopic dermatitis?

Thymopentin improved none of 10 patients in a randomized case-controlled atopic dermatitis study that compared it with interferon alpha and interferon gamma ^[8].

That study, in a specific dermatitis subtype, found improvement in 11 of 13 patients on interferon alpha and 2 of 10 on interferon gamma, versus zero of ten on thymopentin ^[8]. Broader systematic reviews of systemic atopic dermatitis treatments list thymopentin among the agents studied. The treatments those reviews identify as having consistent supporting evidence are cyclosporine, azathioprine, and methotrexate, and thymopentin is not among them ^[4].

A 2025 pediatric systematic review confirms that thymopentin remains in the literature as a studied systemic option, and it does not single thymopentin out as an evidence-backed choice ^[2].

Does thymopentin prevent myasthenia gravis relapse?

Thymopentin lowered relapse rates and raised remission rates in one randomized trial of 135 patients with myasthenia gravis after extended thymectomy ^[5].

The trial compared prednisone plus pyridostigmine alone against the same regimen plus thymopentin. The thymopentin group had significantly higher remission rates and lower relapse rates, particularly among pediatric patients ^[5].

The result is the more favorable side of the thymopentin record: a real, statistically significant positive RCT. It is also a single trial in one specific post-surgical population.

Does thymopentin improve hepatitis B vaccine response?

Thymopentin did not significantly improve hepatitis B vaccine seroresponse overall in a meta-analysis of 11 controlled trials and 272 dialysis patients ^[3].

The pooled odds ratio was 0.677 (95% CI 0.285 to 1.605). A subgroup analysis restricted to higher-dose regimens did show significant benefit (odds ratio 0.184, 95% CI 0.085 to 0.398) ^[3]. Benefit appeared dose-dependent and was not consistent across the pooled trial set as a whole.

What thymopentin doses did the trials use?

Thymopentin trials used 50 mg subcutaneously three times weekly in the HIV program ^[6] [7] and intramuscular injection for three months in the myasthenia gravis trial ^[5]. The myasthenia regimen gave thymopentin alongside prednisone and pyridostigmine ^[5].

Those are historical trial regimens. Thymopentin never secured FDA approval, and none of the cited studies establishes a current recommended dose, route, or regulatory status, or confirms present-day availability outside research settings.

Has thymopentin been tested for general immune support?

None of the cited trials tested thymopentin in healthy people for general immune support, the population current supplement marketing targets. Every cited controlled trial enrolled patients with a specific diagnosed condition.

Two other questions remain open:

• Dose generalization. Whether the dose-response signal in the hepatitis B vaccine subgroup generalizes to other uses is untested.
• The parent-protein question. Whether the TMPO/LAP2 gene finding has any bearing on what TP-5 does in these trials is an open question that none of the clinical literature addresses.